global action plan on antimicrobial resistance, marc sprenger
TRANSCRIPT
Global action plan on antimicrobial resistance
Global Action Plan on
Antimicrobial Resistance
Dr Marc Sprenger
Director, Antimicrobial Resistance Secretariat
[Presented at the ECDC 10 year Anniversary Event,
22 September 2015, Stockholm]
Global action plan on antimicrobial resistance
Global action plan on antimicrobial resistance
World Health Assembly 2015
WHO Executive Board January 2015Strong support to take plan to World Health Assembly
World Health Assembly May 2015Global Action Plan adopted – over 50 supporting statements
New resolution to support action – over 60 country sponsors
Global action plan on antimicrobial resistance
Five strategic objectives:
1. Improve awareness and understanding
2. Strengthen the knowledge through surveillance and
research
3. Reduce the incidence of infection
4. Optimize the use of antimicrobial medicines
5. Ensure sustainable investment
Global action plan on antimicrobial resistance
Five strategic objectives, my translation:
1. EAAD / WAAW: handle AB with care
2. Set up lab and surveillance and report
3. Good IPC in hospital
4. AB: only prescription & instruction & duration
5. Invest in R&D
Global action plan on antimicrobial resistance
After 20h flight: reality check
Global action plan on antimicrobial resistance
No prescription needed, just take 2
Global action plan on antimicrobial resistance
No knowledge, no instruction
Global action plan on antimicrobial resistance
Listening to her reality…
Global action plan on antimicrobial resistance
What did they tell me…
No medical microbiology lab in main hospital
No infection and prevention control in hospital
No drug regulation
No knowledge, no awareness
No money for GP
But committed local people and Country Office WHO
Global action plan on antimicrobial resistance
Questions for Scientific Panel Discussants:
• Do you see any of ECDC’s core activities as being of
more importance than the others in respect of ECDC’s
role in the next ten years in respect to AMR and the
expectations of stakeholders, and if so why?
• Who will ECDC need to work with over the next ten
years to support Member States (and other
stakeholders) in responding to AMR?
• Are there any significant barriers or issues that ECDC
will need to be mindful of?
Global action plan on antimicrobial resistance
Thank you